amantadine has been researched along with methylphenidate in 35 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (17.14) | 18.7374 |
| 1990's | 1 (2.86) | 18.2507 |
| 2000's | 14 (40.00) | 29.6817 |
| 2010's | 12 (34.29) | 24.3611 |
| 2020's | 2 (5.71) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Ahman, M; Holmén, AG; Wan, H | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jeste, DV; Wyatt, RJ | 1 |
| Costall, B; Naylor, RJ | 3 |
| Ananth, J; Ruskin, R | 1 |
| Cashin, CH; Sutton, S | 1 |
| Morris, K | 1 |
| Rosati, DL | 1 |
| Christodoulou, C; Krupp, LB | 1 |
| Fleminger, S; Greenwood, RJ; Oliver, DL | 2 |
| Collins, L; Silver, BV; Zidek, KA | 1 |
| Blackman, JA; Buck, ML; Conaway, MR; Patrick, PD | 1 |
| Elovic, EP; Napolitano, E; Qureshi, AI | 1 |
| Pachler, M; Scahill, L | 1 |
| Barrett, AM; Gonzalez Rothi, LJ; Levy, CE | 1 |
| Lombardi, F | 1 |
| Elsner, F; Krumm, N; Peuckmann, V; Radbruch, L; Trottenberg, P | 1 |
| Meehan, WP | 1 |
| Akhondzadeh, S; Kazemi, MR; Mohammadi, MR; Rezazadeh, SA; Tabrizi, M; Zia, E | 1 |
| Li, R; Mao, S; Yang, R; Zhao, Z | 1 |
| Callaway, CW; Reynolds, JC; Rittenberger, JC | 1 |
| Cossu, G | 1 |
| Cuhls, H; Minton, O; Mücke, M; Peuckmann-Post, V; Radbruch, L; Stone, P | 1 |
| Canning, SD; Wang, XP; Zhang, LL | 1 |
| Luauté, J; Plantier, D; Tell, L; Wiart, L | 1 |
| Nourbakhsh, B; Revirajan, N; Waubant, E | 1 |
| Aljarallah, S; Auvray, C; Cordano, C; Creasman, J; Jin, C; Krysko, K; Manguinao, M; McCulloch, C; Morris, B; Mowry, E; Nourbakhsh, B; Revirajan, N; Rutatangwa, A; Waubant, E | 1 |
| Bourdette, D | 1 |
13 review(s) available for amantadine and methylphenidate
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
In search of treatment for tardive dyskinesia: review of the literature.
Topics: Amantadine; Antipsychotic Agents; Diagnosis, Differential; Dyskinesia, Drug-Induced; Humans; Levodopa; Lithium; Methylphenidate; Parasympatholytics; Parasympathomimetics; Patient Dropouts; Research Design | 1979 |
Fatigue in multiple sclerosis.
Topics: Amantadine; Autoimmune Diseases; Benzhydryl Compounds; Brain; Case Management; Central Nervous System Stimulants; Combined Modality Therapy; Cross-Over Studies; Depression; Double-Blind Method; Fatigue; Hot Temperature; Humans; Hypothalamus; Methylphenidate; Modafinil; Multiple Sclerosis; Patient Care Team; Pemoline; Physical Therapy Modalities; Pilot Projects; Randomized Controlled Trials as Topic; Self-Assessment; Severity of Illness Index; Tomography, Emission-Computed | 2001 |
Pharmacological management for agitation and aggression in people with acquired brain injury.
Topics: Adrenergic beta-Antagonists; Aggression; Amantadine; Anxiety; Brain Injuries; Humans; Methylphenidate; Neuroprotective Agents; Pindolol; Propranolol; Randomized Controlled Trials as Topic | 2003 |
Pharmacological stimulant treatment of neurocognitive and functional deficits after traumatic and non-traumatic brain injury.
Topics: Amantadine; Animals; Brain Injuries; Bromocriptine; Cognition Disorders; Dextroamphetamine; Humans; Levodopa; Methylphenidate | 2005 |
Pharmacological management for agitation and aggression in people with acquired brain injury.
Topics: Adrenergic beta-Antagonists; Aggression; Amantadine; Anxiety; Brain Injuries; Humans; Methylphenidate; Neuroprotective Agents; Pindolol; Propranolol; Psychomotor Agitation; Randomized Controlled Trials as Topic | 2006 |
Treatment of hyperactivity in children with pervasive developmental disorders.
Topics: Adrenergic alpha-Agonists; Amantadine; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Child Development Disorders, Pervasive; Child Psychiatry; Dopamine Agents; Guanfacine; Humans; Methylphenidate; Naltrexone; Narcotic Antagonists; Patient Selection; Treatment Outcome | 2007 |
Pharmacological treatments for fatigue associated with palliative care.
Topics: Adult; Amantadine; Benzhydryl Compounds; Central Nervous System Stimulants; Fatigue; Humans; Kidney Failure, Chronic; Methylphenidate; Modafinil; Multiple Sclerosis; Neoplasms; Palliative Care; Pemoline; Randomized Controlled Trials as Topic | 2010 |
Medical therapies for concussion.
Topics: Amantadine; Analgesics, Non-Narcotic; Antiparkinson Agents; Athletic Injuries; Brain Concussion; Brain Injuries; Central Nervous System Stimulants; Cognition; Cognition Disorders; Humans; Methylphenidate; Sleep Wake Disorders; Sports Medicine; Trauma Severity Indices | 2011 |
Therapeutic options to enhance coma arousal after traumatic brain injury: state of the art of current treatments to improve coma recovery.
Topics: Amantadine; Arousal; Brain Injuries; Cell Transplantation; Central Nervous System Stimulants; Coma; Deep Brain Stimulation; Dopamine Agents; Drug Therapy; Electric Stimulation Therapy; Glasgow Coma Scale; Humans; Hyperbaric Oxygenation; Median Nerve; Methylphenidate; Recovery of Function; Spinal Cord; Transcranial Magnetic Stimulation; Treatment Outcome | 2014 |
Pharmacological treatments for fatigue associated with palliative care.
Topics: Adult; Amantadine; Benzhydryl Compounds; Carnitine; Central Nervous System Stimulants; Chronic Disease; Fatigue; Humans; Kidney Failure, Chronic; Methylphenidate; Modafinil; Multiple Sclerosis; Neoplasms; Palliative Care; Pemoline; Randomized Controlled Trials as Topic | 2015 |
Freezing of Gait in Parkinsonism and its Potential Drug Treatment.
Topics: Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Botulinum Toxins; Droxidopa; Gait Disorders, Neurologic; Humans; Indans; Levodopa; Methylphenidate; Middle Aged; Monoamine Oxidase Inhibitors; Parkinsonian Disorders; Selegiline; Treatment Outcome | 2016 |
Care management of the agitation or aggressiveness crisis in patients with TBI. Systematic review of the literature and practice recommendations.
Topics: Adrenergic beta-Antagonists; Aggression; Amantadine; Anti-Anxiety Agents; Anticonvulsants; Antipsychotic Agents; Benzodiazepines; Brain Injuries; Buspirone; Central Nervous System Stimulants; Dopamine Agents; Humans; Methylphenidate; Psychomotor Agitation; Restraint, Physical | 2016 |
3 trial(s) available for amantadine and methylphenidate
| Article | Year |
|---|---|
Amantadine versus methylphenidate in children and adolescents with attention deficit/hyperactivity disorder: a randomized, double-blind trial.
Topics: Adolescent; Amantadine; Attention Deficit Disorder with Hyperactivity; Child; Dopamine Agents; Dopamine Uptake Inhibitors; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Methylphenidate; Psychiatric Status Rating Scales; Treatment Outcome | 2010 |
Treatment of fatigue with methylphenidate, modafinil and amantadine in multiple sclerosis (TRIUMPHANT-MS): Study design for a pragmatic, randomized, double-blind, crossover clinical trial.
Topics: Amantadine; Central Nervous System Stimulants; Cross-Over Studies; Double-Blind Method; Fatigue; Humans; Methylphenidate; Modafinil; Multiple Sclerosis; Research Design | 2018 |
Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial.
Topics: Adult; Amantadine; Central Nervous System Stimulants; Cross-Over Studies; Double-Blind Method; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Fatigue; Female; Humans; Male; Methylphenidate; Middle Aged; Modafinil; Multiple Sclerosis; Outcome Assessment, Health Care; Severity of Illness Index | 2021 |
19 other study(ies) available for amantadine and methylphenidate
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
Topics: Brain; Central Nervous System; Chromatography, Liquid; Emulsions; Mass Spectrometry | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
A comparison of circling models for the detection of antiparkinson activity.
Topics: Amantadine; Animals; Antiparkinson Agents; Apomorphine; Behavior; Brain; Dextroamphetamine; Dopamine; Haloperidol; Humans; Isoquinolines; Levodopa; Male; Methylphenidate; Methyltyrosines; Piperazines; Rats; Reserpine; Rotation; Stereotaxic Techniques; Stereotyped Behavior; Substantia Nigra; Thalamic Nuclei | 1975 |
Actions of dopaminergic agonists on motor function.
Topics: Amantadine; Animals; Apomorphine; Behavior; Dextroamphetamine; Disease Models, Animal; Dopamine Antagonists; Humans; Hyperkinesis; Levodopa; Methylphenidate; Motor Activity; Movement Disorders; Phenethylamines; Piribedil; Rats; Stereotyped Behavior; Tyrosine | 1975 |
Dopamine agonist and antagonist activities of piribedil (ET495)and its metabolites.
Topics: Amantadine; Amphetamine; Animals; Apomorphine; Atropine; Behavior, Animal; Caudate Nucleus; Dextroamphetamine; Dioxoles; Dopamine; Dopamine Antagonists; Drug Synergism; Haloperidol; Humans; Injections; Male; Methylphenidate; Motor Activity; Nialamide; Piperazines; Pyrimidines; Rats; Stereotyped Behavior; Sulfites | 1974 |
Treatment of intractable depression.
Topics: Amantadine; Antidepressive Agents; Depression; Dextroamphetamine; Drug Therapy, Combination; Hormones; Humans; Lithium; Methylphenidate; Monoamine Oxidase Inhibitors; Reserpine; Sleep Deprivation; Tryptophan; Vitamins | 1974 |
The effect of anti-Parkinson drugs on catalepsy induced by -methyl-p-tyrosine in rats pretreated with intraventricular 6-hydroxydopamine.
Topics: Amantadine; Amphetamine; Animals; Antiparkinson Agents; Apomorphine; Benserazide; Benztropine; Brain Chemistry; Catalepsy; Dextroamphetamine; Dihydroxyphenylalanine; Humans; Hydroxydopamines; Methylphenidate; Methyltyrosines; Rats; Reserpine; Scopolamine | 1973 |
Seeking ways to crack cocaine addiction.
Topics: Amantadine; Clinical Trials as Topic; Cocaine-Related Disorders; Dopamine Uptake Inhibitors; Humans; Ibogaine; Methylphenidate; Selegiline | 1998 |
Early polyneuropharmacologic intervention in brain injury agitation.
Topics: Adolescent; Adult; Amantadine; Antipsychotic Agents; Brain Injuries; Dextroamphetamine; Drug Administration Schedule; Drug Therapy, Combination; Follow-Up Studies; Humans; Hypnotics and Sedatives; Injury Severity Score; Longitudinal Studies; Male; Methylphenidate; Middle Aged; Neuropharmacology; Psychomotor Agitation; Trauma Centers; Trazodone; Treatment Outcome | 2002 |
Risperidone treatment of motor restlessness following anoxic brain injury.
Topics: Adolescent; Amantadine; Brain Injuries; Dopamine Agents; Drug Therapy, Combination; Humans; Hypoxia, Brain; Male; Methylphenidate; Psychomotor Agitation; Risperidone; Serotonin Antagonists; Treatment Outcome | 2003 |
The use of dopamine enhancing medications with children in low response states following brain injury.
Topics: Adolescent; Adult; Amantadine; Arousal; Awareness; Benzothiazoles; Brain Injuries; Bromocriptine; Child; Dopamine Agents; Dopamine Agonists; Female; Humans; Levodopa; Male; Methylphenidate; Neuropsychological Tests; Pramipexole; Retrospective Studies; Thiazoles; Treatment Outcome; Unconsciousness | 2003 |
Pharmaceuticals for poststroke and brain injury rehabilitation.
Topics: Amantadine; Aphasia, Broca; Brain Injuries; Dopamine Agents; Humans; Methylphenidate; Persistent Vegetative State; Stroke; Stroke Rehabilitation | 2007 |
Pharmacological treatment of neurobehavioural sequelae of traumatic brain injury.
Topics: Amantadine; Animals; Antidepressive Agents; Antipsychotic Agents; Brain Injuries; Cognition; Cognition Disorders; Guidelines as Topic; Humans; Methylphenidate; Nervous System Diseases; Neurology; Psychomotor Agitation; Selective Serotonin Reuptake Inhibitors | 2008 |
Several concerns arise when the results are interpreted.
Topics: Amantadine; Attention Deficit Disorder with Hyperactivity; Dopamine Agents; Dopamine Uptake Inhibitors; Female; Humans; Male; Methylphenidate | 2011 |
Methylphenidate and amantadine to stimulate reawakening in comatose patients resuscitated from cardiac arrest.
Topics: Adult; Aged; Amantadine; Cardiopulmonary Resuscitation; Central Nervous System Stimulants; Cohort Studies; Coma; Female; Heart Arrest; Humans; Male; Methylphenidate; Middle Aged; Patient Discharge; Retrospective Studies; Survival Rate; Treatment Outcome; Young Adult | 2013 |
Are drugs for multiple sclerosis fatigue just placebos?
Topics: Amantadine; Double-Blind Method; Fatigue; Humans; Methylphenidate; Modafinil; Multiple Sclerosis; Pharmaceutical Preparations | 2021 |